294 related articles for article (PubMed ID: 25194020)
1. Impact of efficacy at the μ-opioid receptor on antinociceptive effects of combinations of μ-opioid receptor agonists and cannabinoid receptor agonists.
Maguire DR; France CP
J Pharmacol Exp Ther; 2014 Nov; 351(2):383-9. PubMed ID: 25194020
[TBL] [Abstract][Full Text] [Related]
2. Interactions between μ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration.
Maguire DR; Yang W; France CP
J Pharmacol Exp Ther; 2013 Jun; 345(3):354-62. PubMed ID: 23536317
[TBL] [Abstract][Full Text] [Related]
3. Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl.
Maguire DR; France CP
Eur J Pharmacol; 2016 Aug; 784():199-206. PubMed ID: 27184925
[TBL] [Abstract][Full Text] [Related]
4. Combined Treatment with Morphine and Δ9-Tetrahydrocannabinol in Rhesus Monkeys: Antinociceptive Tolerance and Withdrawal.
Gerak LR; France CP
J Pharmacol Exp Ther; 2016 May; 357(2):357-66. PubMed ID: 26937020
[TBL] [Abstract][Full Text] [Related]
5. Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: Impact of drug and fixed-dose ratio.
Maguire DR; France CP
Eur J Pharmacol; 2018 Jan; 819():217-224. PubMed ID: 29183835
[TBL] [Abstract][Full Text] [Related]
6. Cross-tolerance to cannabinoids in morphine-tolerant rhesus monkeys.
Gerak LR; Zanettini C; Koek W; France CP
Psychopharmacology (Berl); 2015 Oct; 232(19):3637-47. PubMed ID: 26202613
[TBL] [Abstract][Full Text] [Related]
7. Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception.
Li JX; McMahon LR; Gerak LR; Becker GL; France CP
Psychopharmacology (Berl); 2008 Aug; 199(2):199-208. PubMed ID: 18470505
[TBL] [Abstract][Full Text] [Related]
8. Interactive effects of (±)-trans-U50488 and its stereoisomers with cannabinoids.
Erwin LL; Nilges MR; Denys IB; Sutphen JC; Friend AJ; Kapusta DR; Winsauer PJ
Pharmacol Biochem Behav; 2021 Aug; 207():173218. PubMed ID: 34118232
[TBL] [Abstract][Full Text] [Related]
9. Reinforcing effects of opioid/cannabinoid mixtures in rhesus monkeys responding under a food/drug choice procedure.
Maguire DR; France CP
Psychopharmacology (Berl); 2018 Aug; 235(8):2357-2365. PubMed ID: 29860612
[TBL] [Abstract][Full Text] [Related]
10. Ventilatory-depressant effects of opioids alone and in combination with cannabinoids in rhesus monkeys.
Weed PF; Gerak LR; France CP
Eur J Pharmacol; 2018 Aug; 833():94-99. PubMed ID: 29807027
[TBL] [Abstract][Full Text] [Related]
11. Antinociceptive effects of monoamine reuptake inhibitors administered alone or in combination with mu opioid agonists in rhesus monkeys.
Gatch MB; Negus SS; Mello NK
Psychopharmacology (Berl); 1998 Jan; 135(1):99-106. PubMed ID: 9489939
[TBL] [Abstract][Full Text] [Related]
12. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
13. Functional consequences of short-term exposure to opioids versus cannabinoids in nonhuman primates.
Ding H; Kiguchi N; Mabry KM; Kishioka S; Ko MC
Neuropharmacology; 2023 Feb; 223():109328. PubMed ID: 36356937
[TBL] [Abstract][Full Text] [Related]
14. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.
Tham SM; Angus JA; Tudor EM; Wright CE
Br J Pharmacol; 2005 Mar; 144(6):875-84. PubMed ID: 15778704
[TBL] [Abstract][Full Text] [Related]
15. Differential tolerance to antinociceptive effects of mu opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats.
Walker EA; Young AM
Psychopharmacology (Berl); 2001 Mar; 154(2):131-42. PubMed ID: 11314675
[TBL] [Abstract][Full Text] [Related]
16. Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception.
Stevenson GW; Folk JE; Linsenmayer DC; Rice KC; Negus SS
J Pharmacol Exp Ther; 2003 Dec; 307(3):1054-64. PubMed ID: 14557380
[TBL] [Abstract][Full Text] [Related]
17. Role of delta opioid efficacy as a determinant of mu/delta opioid interactions in rhesus monkeys.
Negus SS; Bear AE; Folk JE; Rice KC
Eur J Pharmacol; 2009 Jan; 602(1):92-100. PubMed ID: 19027735
[TBL] [Abstract][Full Text] [Related]
18. Effects of opioid/cannabinoid mixtures on impulsivity and memory in rhesus monkeys.
Minervini V; France CP
Behav Pharmacol; 2020 Apr; 31(2&3):233-248. PubMed ID: 32101988
[TBL] [Abstract][Full Text] [Related]
19. Behavioral Characterization of κ Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats.
Minervini V; Dahal S; France CP
J Pharmacol Exp Ther; 2017 Feb; 360(2):280-287. PubMed ID: 27903642
[TBL] [Abstract][Full Text] [Related]
20. Interactions between kappa and mu opioid receptor agonists: effects of the ratio of drugs in mixtures.
Minervini V; Lu HY; Padarti J; Osteicoechea DC; France CP
Psychopharmacology (Berl); 2018 Aug; 235(8):2245-2256. PubMed ID: 29785554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
